Home > Compound List > Product Information
Amiloride_Molecular_structure_CAS_2016-88-8)
Click picture or here to close

Amiloride

Catalog No. DB00594 Name DrugBank
CAS Number 2016-88-8 Website http://www.ualberta.ca/
M. F. C6H8ClN7O Telephone (780) 492-3111
M. W. 229.62702 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 476

SYNONYMS

IUPAC name
3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
IUPAC Traditional name
amiloride
Brand Name
Amiprazidine
Guanamprazin
Amipramidin
Amipramizid
Amipramizide
Guanamprazine
Midamor
Synonyms
Amyloride
Amiloridum [INN-Latin]
Amiloride hydrochloride hydrate
Amiloride hydrochloride
Amiloride HCL
Amilorida [INN-Spanish]
AMR

DATABASE IDS

CAS Number 2016-88-8
PubChem SID 46508156
PubChem CID 16231

PROPERTIES

Hydrophobicity(logP) -0.3
Solubility Slightly soluble

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
Indication For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.
Pharmacology Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements.
Toxicity No data are available in regard to overdosage in humans. The oral LD50 of amiloride hydrochloride (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance.
Affected Organisms
Humans and other mammals
Biotransformation Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.
Absorption Readily absorbed following oral administration.
Half Life Plasma half-life varies from 6 to 9 hours.
Elimination Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys. About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours.
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES